Curacell

Executive Summary

Curacell is a private Swedish biotechnology company developing cell-based immunotherapies for solid tumors, leveraging its proprietary CytoPLY™ T-cell activation and enrichment platform. Founded in 2016 and headquartered in Stockholm, the company focuses on Tumor-Infiltrating Lymphocyte (TIL) therapy for late-stage prostate and colorectal cancers, aiming to achieve durable cures. Curacell's approach involves isolating and expanding TILs from patient tumors, then reinfusing them after activation and enrichment to enhance antitumor activity. The company is at a preclinical to early clinical stage, with no disclosed financing rounds or valuation, indicating a need for capital to advance its lead candidate. If successful, Curacell could address significant unmet needs in solid tumor oncology, where current immunotherapies have limited efficacy.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1/2 clinical trial for TIL therapy in prostate cancer60% success
• H2 2026Partnership or licensing deal for CytoPLY platform40% success
• Q2 2026Peer-reviewed publication of preclinical efficacy data80% success